CC-1, PSMAxCD3

Phase 1Small molecule

UUniversity Hospital Tuebingen

CC-1, PSMAxCD3 is one of 37 small molecule programs targeting Prostate Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CarcinomaRecruiting

Prostate CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

39 competitors in Prostate Carcinoma

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Approved

2 2

Nubeqa

Bayer

Approved

2 3

Xtandi

Astellas

Approved

1 4

Ritalin

Novartis

Approved

1 5

Zometa

Pfizer

Approved

—6

Lupron

Sun Pharmaceutical Industries, Inc.

Lynparza

Estrace

Balversa

Jevtana

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Carcinoma1 trial

The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

Recruiting·UUniversity Hospital Tuebingen·Phase 1·NCT04104607·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CC-1, PSMAxCD3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-1, PSMAxCD3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-1, PSMAxCD3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Tuebingen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospital Tuebingen

CC-1, PSMAxCD3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News